IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds

被引：33

作者：

Margolskee, Alison ^{[1
]}

Darwich, Adam S. ^{[1
]}

Pepin, Xavier ^{[2
,3
]}

Pathak, Shriram M. ^{[4
]}

Bolger, Michael B. ^{[5
]}

Aarons, Leon ^{[1
]}

Rostami-Hodjegan, Amin ^{[1
,4
]}

Angstenberger, Jonas ^{[6
]}

Graf, Franziska ^{[6
]}

Laplanche, Loic ^{[6
]}

Mueller, Thomas ^{[6
]}

Carlert, Sara ^{[7
]}

Daga, Pankaj ^{[8
]}

Murphy, Donal ^{[2
]}

Tannergren, Christer ^{[7
]}

Yasin, Mohammed ^{[2
]}

Greschat-Schade, Susanne ^{[9
]}

Mueck, Wolfgang ^{[9
]}

Muenster, Uwe ^{[9
]}

van der Mey, Dorina ^{[9
]}

Frank, Kerstin Julia ^{[10
]}

Lloyd, Richard ^{[11
]}

Adriaenssen, Lieve ^{[12
]}

Bevernage, Jan ^{[12
]}

De Zwart, Loeckie ^{[12
]}

Swerts, Dominique ^{[12
]}

Tistaert, Christophe ^{[12
]}

Van Den Bergh, An ^{[12
]}

Van Peer, Achiel ^{[12
]}

Beato, Stefania ^{[13
]}

Anh-Thu Nguyen-Trung ^{[13
]}

Bennett, Joanne ^{[14
]}

McAllister, Mark ^{[14
]}

Wong, Mei ^{[14
]}

Zane, Patricia ^{[15
]}

Ollier, Celine ^{[3
]}

Vicat, Pascale ^{[3
]}

Kolhmann, Markus ^{[16
]}

Marker, Alexander ^{[3
]}

Brun, Priscilla ^{[3
]}

Mazuir, Florent ^{[3
]}

Beilles, Stephane ^{[3
]}

Venczel, Marta ^{[16
]}

Boulenc, Xavier ^{[3
]}

Loos, Petra ^{[16
]}

Lennernas, Hans ^{[17
]}

Abrahamsson, Bertil ^{[7
]}

机构：

[1] Univ Manchester, Manchester M13 9PL, Lancs, England

[2] AstraZeneca, London, England

[3] Sanofi, Paris, France

[4] Simcyp Ltd, Sheffield, S Yorkshire, England

[5] Simulat Plus Inc, Lancaster, CA USA

[6] AbbVie, Wiesbaden, Germany

[7] AstraZeneca, Gothenburg, Sweden

[8] AstraZeneca, New York, NY USA

[9] Bayer Pharma AG, Berlin, Germany

[10] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[11] GlaxoSmithKline, Brentford, Middx, England

[12] Janssen, Beerse, Belgium

[13] Novartis, Basel, Switzerland

[14] Pfizer, Tadworth, Middx, England

[15] Sanofi, Bridgewater, NJ USA

[16] Sanofi, Frankfurt, Germany

[17] Uppsala Univ, Uppsala, Sweden

来源：

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2017年 / 96卷

关键词：

Physiologically-based pharmacokinetics (PBPK); Modelling and simulation (M&S); Absorption; Oral bioavailability (F-oral); Biopharmaceutics; Drug database; HUMAN PHARMACOKINETICS; QUANTITATIVE PREDICTION; DRUG ABSORPTION; MODEL; CLASSIFICATION; PERMEABILITY; SIMULATION; PARAMETERS; PERFUSION; HUMANS;

D O I：

10.1016/j.ejps.2016.09.027

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Predicting oral bioavailability (F-oral) is of importance for estimating systemic exposure of orally administered drugs. Physiologically-based pharmacokinetic (PBPK) modelling and simulation have been applied extensively in biopharmaceutics recently. The Oral Biopharmaceutical Tools (OrBiTo) project (Innovative Medicines Initiative) aims to develop and improve upon biopharmaceutical tools, including PBPK absorption models. A large-scale evaluation of PBPK models may be considered the first step. Here we characterise the OrBiTo active pharmaceutical ingredient (API) database for use in a large-scale simulation study. The OrBiTo database comprised 83 APIs and 1475 study arms. The database displayed a median logP of 3.60 (2.40-4.58), human blood-to-plasma ratio of 0.62 (0.57-0.71), and fraction unbound in plasma of 0.05 (0.01-0.17). The database mainly consisted of basic compounds (48.19%) and Biopharmaceutics Classification System class II compounds (55.81%). Median human intravenous clearance was 16.9 L/h (interquartile range: 11.6-43.6 L/h; n = 23), volume of distribution was 80.8 L (54.5-239 L; n = 23). The majority of oral formulations were immediate release (IR: 87.6%). Human Foral displayed a median of 0.415 (0.203-0.724; n = 22) for IR formulations. The OrBiTo database was found to be largely representative of previously published datasets. 43 of the APIs were found to satisfy the minimum inclusion criteria for the simulation exercise, and many of these have significant gaps of other key parameters, which could potentially impact the interpretability of the simulation outcome. However, the OrBiTo simulation exercise represents a unique opportunity to perform a large-scale evaluation of the PBPK approach to predicting oral biopharmaceutics. (C) 2016 Elsevier B.V. All rights reserved.

引用

页码：598 / 609

页数：12

共 25 条

[1] A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY
AMIDON, GL
LENNERNAS, H
SHAH, VP
CRISON, JR
[J]. PHARMACEUTICAL RESEARCH, 1995, 12 (03) : 413 - 420
[2] BDDCS Applied to Over 900 Drugs
Benet, Leslie Z.
Broccatelli, Fabio
Oprea, Tudor I.
[J]. AAPS JOURNAL, 2011, 13 (04): : 519 - 547
[3] A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: Structure-kinetics relationship assessment
Bu, HZ
[J]. CURRENT DRUG METABOLISM, 2006, 7 (03) : 231 - 249
[4] RENEWAL OF EPITHELIUM IN DESCENDING COLON OF MOUSE .1. PRESENCE OF 3 CELL POPULATIONS - VACUOLATED-COLUMNAR, MUCOUS AND ARGENTAFFIN
CHANG, WWL
LEBLOND, CP
[J]. AMERICAN JOURNAL OF ANATOMY, 1971, 131 (01): : 73 - +
[5] Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs
De Buck, Stefan S.
Sinha, Vikash K.
Fenu, Luca A.
Nijsen, Marjoleen J.
Mackie, Claire E.
Gilissen, Ron A. H. J.
[J]. DRUG METABOLISM AND DISPOSITION, 2007, 35 (10) : 1766 - 1780
[6] FDA, 2000, GUID IND WAIV IN VIV
[7] Impact of sleep disorders in Japanese patients with functional dyspepsia (FD): Nizatidine improves clinical symptoms, gastric emptying and sleep disorders in FD patients
Futagami, Seiji
Yamawaki, Hiroshi
Izumi, Nikki
Shimpuku, Mayumi
Kodaka, Yasuhiro
Wakabayashi, Taiga
Nagoya, Hiroyuki
Shindo, Tomotaka
Kawagoe, Tetsuro
Gudis, Katya
Itoh, Takashi
Sakamoto, Choitsu
[J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (08) : 1314 - 1320
[8] Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches
Hosea, Natilie A.
Collard, Wendy T.
Cole, Susan
Maurer, Tristan S.
Fang, Rick X.
Jones, Hannah
Kakar, Shefali M.
Nakai, Yasuhiro
Smith, Bill J.
Webster, Rob
Beaumont, Kevin
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (05) : 513 - 533
[9] The Utility of Modeling and Simulation in Drug Development and Regulatory Review
Huang, Shiew-Mei
Abernethy, Darrell R.
Wang, Yaning
Zhao, Ping
Zineh, Issam
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (09) : 2912 - 2923
[10] Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling
Jones, Hannah M.
Gardner, Iain B.
Collard, Wendy T.
Stanley, Phil J.
Oxley, Penny
Hosea, Natilie A.
Plowchalk, David
Gernhardt, Steve
Lin, Jing
Dickins, Maurice
Rahavendran, S. Ravi
Jones, Barry C.
Watson, Kenny J.
Pertinez, Henry
Kumar, Vikas
Cole, Susan
[J]. CLINICAL PHARMACOKINETICS, 2011, 50 (05) : 331 - 347

← 1 2 3 →